RAPT Therapeutics, Inc. (RAPT)
NASDAQ: RAPT · Real-Time Price · USD
57.74
-0.03 (-0.05%)
At close: Feb 10, 2026, 4:00 PM EST
57.70
-0.04 (-0.07%)
After-hours: Feb 10, 2026, 5:12 PM EST
RAPT Therapeutics Employees
RAPT Therapeutics had 60 employees as of September 30, 2025. The number of employees decreased by 10 or -14.29% compared to the same quarter last year.
Employees
60
Change
-10
Growth
-14.29%
Revenue / Employee
n/a
Profits / Employee
-$1,760,617
Market Cap
1.79B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 60 | -10 | -14.29% |
| Jun 30, 2025 | 61 | -61 | -50.00% |
| Mar 31, 2025 | 67 | -59 | -46.83% |
| Dec 31, 2024 | 68 | -63 | -48.09% |
| Sep 30, 2024 | 70 | -59 | -45.74% |
| Jun 30, 2024 | 122 | 0 | - |
| Mar 31, 2024 | 126 | 15 | 13.51% |
| Dec 31, 2023 | 131 | 34 | 35.05% |
| Sep 30, 2023 | 129 | 35 | 37.23% |
| Jun 30, 2023 | 122 | 34 | 38.64% |
| Mar 31, 2023 | 111 | 28 | 33.73% |
| Dec 31, 2022 | 97 | 16 | 19.75% |
| Sep 30, 2022 | 94 | 13 | 16.05% |
| Jun 30, 2022 | 88 | 19 | 27.54% |
| Mar 31, 2022 | 83 | 16 | 23.88% |
| Dec 31, 2021 | 81 | 13 | 19.12% |
| Sep 30, 2021 | 81 | 10 | 14.08% |
| Jun 30, 2021 | 69 | -2 | -2.82% |
| Mar 31, 2021 | 67 | -1 | -1.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MannKind | 407 |
| Ardelyx | 395 |
| Vericel | 357 |
| Nurix Therapeutics | 317 |
| Syndax Pharmaceuticals | 270 |
| Zymeworks | 263 |
| Stoke Therapeutics | 128 |
| Pharvaris | 118 |
RAPT News
- 14 days ago - Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewsWire
- 21 days ago - Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK - GlobeNewsWire
- 21 days ago - RAPT Therapeutics shares surge 64% as GSK agrees $2.2B acquisition - Invezz
- 21 days ago - GSK to buy food allergy drug maker RAPT in $2.2bn deal - The Guardian
- 21 days ago - This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up. - Barrons
- 21 days ago - GSK to buy RAPT Therapeutics for $2.2 billion - Reuters
- 26 days ago - RAPT Therapeutics, Inc. (RAPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire